And Ruigene melanoma dedicated genetic testing products on the market

Studies have shown that melanoma, known as the "king of cancer", has a hidden onset of disease, and targeted and immunotherapy have effectively prolonged the survival of patientsThe results of melanoma gene mutation tests provide more comprehensive treatment options for melanoma patientsit is important to identify tumor-related mutant genes in targeted and immunotherapyAnd Ruigene melanoma specific gene mutation detection products comprehensivecoverage of the NCCN/ CSCO guidelines recommended detection of the core drug target gene, in a "melanoma gene testing special study" in nearly a thousand patients tested more than 90% of the detection of mutation genes, of which 70% of the people received targeted treatment and other opportunitiesrelying on the melanoma database, and Ruigene for targeted genetic testing and detection of mutation interpretation, and issued a specific gene mutation detection report for melanoma, for melanoma targeted drug selection, drug resistance analysis, efficacy assessment, metastasis and prognosis assessment, into the group clinical trials to provide multi-directional information referenceThe special genetic test report is more targeted for the interpretation of tumor mutation site, and the clinical treatment is more instructiveTherefore, the special products for melanoma introduced by Ruigen are of more clinical reference value for the treatment of melanoma patients.